Immunotherapy and next-generation sequencing guided therapy for precision oncology: what have we learnt and what does the future hold?

References

• DeVita VT, Chu EA. History of cancer chemotherapy. Cancer Res. 2008;68(21):8643–8653.
   PubMed Web of Science ®Google Scholar
• Lander ES, Linton LM, Birren B, et al. Initial sequencing and analysis of the human genome. Nature. 2001;409(6822):860–921.
   PubMed Web of Science ®Google Scholar
• Cross D, Burmester JK. The promise of molecular profiling for cancer identification and treatment. Clin Med Res. 2004 2004 Aug;2(3):147–150.
   PubMedGoogle Scholar
• Petty RD, Nicolson MC, Kerr KM, et al. Gene expression profiling in non-small cell lung cancer: from molecular mechanisms to clinical application. Clin Cancer Res. 2004;10(10):3237–3248.
   PubMed Web of Science ®Google Scholar
• The Cost of Sequencing a Human Genome: National Human Genome Research Institute; 2016 [ updated 2016 Jul 6,;2018 Feb 4]. Available from: https://www.genome.gov/27565109/the-cost-of-sequencing-a-human-genome/
   Google Scholar
• Mardis ER. The impact of next-generation sequencing technology on genetics. Trends Genet. 2008;24(3):133–141.
   PubMed Web of Science ®Google Scholar
• Groisberg R, Hong DS, Holla V, et al. Clinical genomic profiling to identify actionable alterations for investigational therapies in patients with diverse sarcomas. Oncotarget. 2017 Jun 13;8(24):39254–39267. PubMed PMID: 28424409; PubMed Central PMCID: PMCPMC5503611.
   PubMedGoogle Scholar
• Groisberg R, Roszik J, Conley A, et al. The role of next-generation sequencing in sarcomas: evolution from light microscope to molecular microscope. Curr Oncol Rep. 2017;19(12):78.
   PubMed Web of Science ®Google Scholar
• Hodi FS, O’Day SJ, McDermott DF, et al. Improved survival with Ipilimumab in patients with metastatic melanoma. New England J Med. 2010;363(8):711–723.
   PubMed Web of Science ®Google Scholar
• Robert C, Long GV, Brady B, et al. Nivolumab in previously untreated melanoma without BRAF mutation. New England J Med. 2015;372(4):320–330. PubMed PMID: 25399552.
   PubMed Web of Science ®Google Scholar
• Robert C, Schachter J, Long GV, et al. Pembrolizumab versus Ipilimumab in advanced melanoma. New England J Med. 2015;372(26):2521–2532.
   PubMed Web of Science ®Google Scholar
• Ferris RL, Blumenschein G Jr., Fayette J, et al. Nivolumab for recurrent squamous-cell carcinoma of the head and neck. New England J Med. 2016;375(19):1856–1867.
   PubMed Web of Science ®Google Scholar
• Lim SH, Sun J-M, Lee S-H, et al. Pembrolizumab for the treatment of non-small cell lung cancer. Expert Opin Biol Ther. 2016;16(3):397–406.
   PubMed Web of Science ®Google Scholar
• Bellmunt J, de Wit R, Vaughn DJ, et al. Pembrolizumab as second-line therapy for advanced urothelial carcinoma. New England J Med. 2017;376(11):1015–1026.
   PubMed Web of Science ®Google Scholar
• Wolchok JD, Chiarion-Sileni V, Gonzalez R et al.Overall survival with combined nivolumab and ipilimumab in advanced melanomaNew England J Med20172017 Oct 05377141345–1356
   PubMed Web of Science ®Google Scholar
• Diggs LP, Hsueh EC. Utility of PD-L1 immunohistochemistry assays for predicting PD-1/PD-L1 inhibitor response. Biomarker Res. 2017 2017 Mar 15;5:12..
   PubMed Web of Science ®Google Scholar
• Tang J, Shalabi A, Hubbard-Lucey VM. Comprehensive analysis of the clinical immuno-oncology landscape. Ann Oncol. 2017. 2017 Dec 07. DOI:10.1093/annonc/mdx755.
   Google Scholar
• Behjati S, Tarpey PS.What is next generation sequencing? Arch Dis Child EP. 2013,2013 Dec;986:236–238.
   PubMed Web of Science ®Google Scholar
• Shyr D, Liu Q. Next generation sequencing in cancer research and clinical application. Biol Proced Online. 2013 2013 Feb 13;15:4..
   PubMed Web of Science ®Google Scholar
• Kamps R, Brandão RD, van den Bosch BJ, et al. Next-generation sequencing in oncology: genetic diagnosis, risk prediction and cancer classification. Int J Mol Sci. 2017;18(2). doi: 10.3390/ijms18020308. 2017 Jan 31.
   PubMed Web of Science ®Google Scholar
• Rozenblum AB, Ilouze M, Dudnik E, et al. Clinical impact of hybrid capture-based next-generation sequencing on changes in treatment decisions in lung cancer. J Thorac Oncol. 2017 Feb;12(2):258–268. PubMed PMID: 27865871. .
   PubMed Web of Science ®Google Scholar
• Gupta A, Connelly C, Frampton G, et al. P2.03b-068 the druggable mutation landscape of lung adenocarcinoma. J Thorac Oncol. 2017;12(1):S977.
   Web of Science ®Google Scholar
• Daber R, Sukhadia S, Morrissette JJ. Understanding the limitations of next generation sequencing informatics, an approach to clinical pipeline validation using artificial data sets. Cancer Genet. 2013 Dec;206(12):441–448.. PubMed PMID: 24528889.
   PubMed Web of Science ®Google Scholar
• Frampton GM, A F, Otto GA, et al. Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing. Nat Biotechnol. 2013 Nov;31(11):1023–1031. PubMed PMID: 24142049; PubMed Central PMCID: PMCPMC5710001.
   PubMed Web of Science ®Google Scholar
• Goswami RS, Luthra R, Singh RR, et al. Identification of factors affecting the success of next-generation sequencing testing in solid tumors. Am J Clin Pathol. 2016 Feb;145(2):222–237. PubMed PMID: 27124905.
   PubMed Web of Science ®Google Scholar
• Malapelle U, Pisapia P, Rocco D, et al. Next generation sequencing techniques in liquid biopsy: focus on non-small cell lung cancer patients. Transl Lung Cancer Res. 2016 Oct;5(5):505–510. PubMed PMID: 27826531; PubMed Central PMCID: PMCPMC5099511.
   PubMed Web of Science ®Google Scholar
• Aguado C, Gimenez-Capitan A, Karachaliou N, et al. Fusion gene and splice variant analyses in liquid biopsies of lung cancer patients. Transl Lung Cancer Res. 2016 Oct;5(5):525–531. PubMed PMID: 27826534; PubMed Central PMCID: PMCPMC5099519.
   PubMed Web of Science ®Google Scholar
• Hyman DM, Puzanov I, Subbiah V et al.Vemurafenib in multiple nonmelanoma cancers with BRAF V600 mutationsNew England J Med20152015 Aug 203738726–736
   PubMed Web of Science ®Google Scholar
• Diamond EL, Subbiah V, Lockhart AC, et al. Vemurafenib for BRAF V600–mutant Erdheim-Chester Disease and Langerhans cell histiocytosis: analysis of data from the histology-independent, Phase 2, open-label VE-BASKET study. JAMA Oncol. 2017 2017 Nov 29. DOI:10.1001/jamaoncol.2017.5029.
   Web of Science ®Google Scholar
• Planchard D, Smit EF, Groen HJM, et al. Dabrafenib plus trametinib in patients with previously untreated BRAF V600E -mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial. Lancet Oncol. 2017;18(10):1307–1316.
   PubMed Web of Science ®Google Scholar
• Subbiah V, Kreitman RJ, Wainberg ZA, et al. Dabrafenib and trametinib treatment in patients with locally advanced or metastatic BRAF V600–mutant anaplastic thyroid cancer. J Clin Oncol. 2017 [2017 oct 26];JCO.2017.73.678. DOI:10.1200/JCO.2017.73.6785
   PubMedGoogle Scholar
• Hong DS, Morris VK, El Osta B, et al. Phase IB study of vemurafenib in combination with irinotecan and cetuximab in patients with metastatic colorectal cancer with BRAFV600E mutation. Cancer Discov. 2016;6(12):1352–1365.
   PubMed Web of Science ®Google Scholar
• Taube JM, Anders RA, Young GD, et al. Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape. Sci Transl Med. 2012 Mar 28;4(127):127ra37. PubMed PMID: 22461641; PubMed Central PMCID: PMCPMC3568523.
   PubMed Web of Science ®Google Scholar
• Sharpe AH. Introduction to checkpoint inhibitors and cancer immunotherapy. Immunol Rev. 2017;276(1):5–8.
   PubMed Web of Science ®Google Scholar
• Zhang X, Sharma PK, Peter Goedegebuure S, et al. Personalized cancer vaccines: targeting the cancer mutanome. Vaccine. 2017;35(7):1094–1100.
   PubMed Web of Science ®Google Scholar
• Angell TE, Lechner MG, Jang JK, et al. MHC class I loss is a frequent mechanism of immune escape in papillary thyroid cancer that is reversed by interferon and selumetinib treatment in vitro. Clin Cancer Res. 2014 Dec 1;20(23):6034–6044. 10.1158/1078-0432.CCR-14-0879. PubMed PMID: 25294906; PubMed Central PMCID: PMCPMC4252612.
   PubMed Web of Science ®Google Scholar
• Del Campo AB, Kyte JA, Carretero J, et al. Immune escape of cancer cells with beta2-microglobulin loss over the course of metastatic melanoma. Int J Cancer. 2014 Jan 1;134(1):102–113. PubMed PMID: 23784959.
   PubMed Web of Science ®Google Scholar
• Bodey B, Bodey B, Siegel SE, et al. Failure of cancer vaccines: the significant limitations of this approach to immunotherapy. Anticancer Res. 20002000 Aug- Jul undefined;204:2665–2676. eng.
   PubMed Web of Science ®Google Scholar
• Rosenberg SA, Yannelli JR, Yang JC, et al. Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2. J Natl Cancer Inst. 19941994 Aug 03;86(15):1159–1166. eng.
   PubMed Web of Science ®Google Scholar
• Neelapu SS, Locke FL, Bartlett NL, et al. Axicabtagene Ciloleucel CAR T-cell therapy in refractory large Lymphoma B-C. New England J Med, 2017 2017 10. 0(0):null doi: 10.1056/NEJMoa1707447
   PubMed Web of Science ®Google Scholar
• Newick K, Moon E, Albelda SM. Chimeric antigen receptor T-cell therapy for solid tumors. Mol Ther Oncolytics. 2016;3(Supplement C):16006.
   PubMedGoogle Scholar
• Atkins MB, Larkin J. Immunotherapy combined or sequenced with targeted therapy in the treatment of solid tumors: current perspectives. J Natl Cancer Inst. 2016 2016 Jun 01;108(6). doi: 10.1093/jnci/djv414.
   PubMedGoogle Scholar
• Gainor JF, Shaw AT, Sequist LV, et al. EGFR mutations and alk rearrangements are associated with low response rates to PD-1 pathway blockade in non-small cell lung cancer: a retrospective analysis. Clin Cancer Res. 2016;22(18):4585–4593.
   PubMed Web of Science ®Google Scholar
• Haratani K, Hayashi H, Tanaka T, et al. Tumor immune microenvironment and nivolumab efficacy in EGFR mutation-positive non-small-cell lung cancer based on T790M status after disease progression during EGFR-TKI treatment. Ann Oncol. 2017;28(7):1532–1539.
   PubMed Web of Science ®Google Scholar
• Hu-Lieskovan S, Robert L, Homet Moreno B, et al. Combining targeted therapy with immunotherapy in BRAF-mutant melanoma: promise and challenges. J Clin Oncol. 2014;32(21):2248–2254.
   PubMed Web of Science ®Google Scholar
• Langer CJ, Gadgeel SM, Borghaei H, et al. Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study. Lancet Oncol. 2016;17(11):1497–1508.
   PubMed Web of Science ®Google Scholar
• Kammerer-Jacquet S-F, Medane S, Bensalah K, et al. Correlation of c-MET expression with PD-L1 expression in metastatic clear cell renal cell carcinoma treated by sunitinib first-line therapy. Targ Oncol. 2017;12(4):487–494.
   PubMed Web of Science ®Google Scholar
• Callahan MK, Masters G, Pratilas CA, et al. Paradoxical activation of T cells via augmented ERK signaling mediated by a RAF inhibitor. Cancer Immunol Res. 2014 2014 Jan;2(1):70–79. CIR-13-0160.
   PubMed Web of Science ®Google Scholar
• Ribas A, Hodi FS, Callahan M, et al. Hepatotoxicity with combination of Vemurafenib and Ipilimumab. New England J Med. 2013;368(14):1365–1366.
   PubMed Web of Science ®Google Scholar
• Ahn M-J, Sun J-M, Lee S-H, et al. EGFR TKI combination with immunotherapy in non-small cell lung cancer. Expert Opin Drug Saf. 2017;16(4):465–469.
   PubMed Web of Science ®Google Scholar
• Karachaliou N, Gonzalez-Cao M, Sosa A, et al. The combination of checkpoint immunotherapy and targeted therapy in cancer. Ann Transl Med. 2017 Oct;5(19):388. PubMed PMID: 29114546; PubMed Central PMCID: PMCPMC5653508.
   PubMed Web of Science ®Google Scholar
• Patel SP, Kurzrock R. PD-L1 expression as a predictive biomarker in cancer immunotherapy. Mol Cancer Ther. 2015 Apr;14(4):847–856. 10.1158/1535-7163.MCT-14-0983. PubMed PMID: 25695955.
   PubMed Web of Science ®Google Scholar
• Roemer MGM, Advani RH, Ligon AH, et al. PD-L1 and PD-L2 genetic alterations define classical hodgkin lymphoma and predict outcome. J Clin Oncol. 2016;34(23):2690–2697.
   PubMed Web of Science ®Google Scholar
• Ansell SM, Lesokhin AM, Borrello I, et al. PD-1 Blockade with nivolumab in relapsed or refractory Hodgkin’s lymphoma. New England J Med. 2015;372(4):311–319.
   PubMed Web of Science ®Google Scholar
• Udall M, Rizzo M, Kenny J, et al. PD-L1 diagnostic tests: a systematic literature review of scoring algorithms and test-validation metrics. Diagn Pathol. 2018 Feb 9;13(1):12. PubMed PMID: 29426340; PubMed Central PMCID: PMCPMC5807740.
   PubMed Web of Science ®Google Scholar
• Bonta I, Isac JF, Meiri E, et al. Correlation between tumor mutation burden and response to immunotherapy. J Clin Oncol. 2017;35(15_suppl):e14579–e14579.
   Google Scholar
• Goodman AM, Kato S, Bazhenova L, et al. Tumor mutational burden as an independent predictor of response to immunotherapy in diverse cancers. Mol Cancer Ther. 2017; molcanther.0386.2017 2017 Jan 01. Doi: 10.1158/1535-7163.MCT-17-0386.
   PubMed Web of Science ®Google Scholar
• Yaghmour G, Pandey M, Ireland C, et al. Role of genomic instability in immunotherapy with checkpoint inhibitors. Anticancer Res. 2016;36(8):4033–4038. en. 2016 Aug 01
   PubMed Web of Science ®Google Scholar
• Roszik J, Haydu LE, Hess KR, et al. Novel algorithmic approach predicts tumor mutation load and correlates with immunotherapy clinical outcomes using a defined gene mutation set. BMC Med. 2016;14:168. 2016 Oct 25..
   PubMed Web of Science ®Google Scholar
• Hanna GJ, Liu H, Jones RE, et al. Defining an inflamed tumor immunophenotype in recurrent, metastatic squamous cell carcinoma of the head and neck. Oral Oncology. 2017;67(Supplement C):61–69.
   PubMedGoogle Scholar
• Alexandrov LB, Nik-Zainal S, Wedge DC, et al. Signatures of mutational processes in human cancer. Nature. 2013 2013 Aug 14;500(7463):nature12477. en.
   Web of Science ®Google Scholar
• Motzer RJ, Escudier B, McDermott DF, et al. Nivolumab versus Everolimus in advanced renal-cell carcinoma. New England J Med. 2015;373(19):1803–1813.
   PubMed Web of Science ®Google Scholar
• Morse CB, Elvin JA, Gay LM, et al. Elevated tumor mutational burden and prolonged clinical response to anti-PD-L1 antibody in platinum-resistant recurrent ovarian cancer. Gynecol Oncol Rep. 2017;21:78–80. 2017 Jun 27..
   PubMed Web of Science ®Google Scholar
• Zehir A, Benayed R, Shah RH, et al. Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients. Nat Med. 2017 Jun;23(6):703–713. PubMed PMID: 28481359; PubMed Central PMCID: PMCPMC5461196.
   PubMed Web of Science ®Google Scholar
• Chalmers ZR, Connelly CF, Fabrizio D, et al. Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden. Genome Med. 2017;9:34. 2017 Apr 19..
   PubMed Web of Science ®Google Scholar
• Westdorp H, Fennemann FL, Weren RDA, et al. Opportunities for immunotherapy in microsatellite instable colorectal cancer. Cancer Immunol Immunother. 2016;65(10):1249–1259.
   PubMed Web of Science ®Google Scholar
• Le DT, Uram JN, Wang H, et al. PD-1 blockade in tumors with deficiency M-R. New England J Med.20152015 Jun 25;37226:2509–2520.
   PubMed Web of Science ®Google Scholar
• Vuzman D, Powers W, Huang X, et al. Tumor mutation burden derived from large NGS panel as biomarker for immunotherapy response. J Clin Oncol. 2017;35(15_suppl):e23077–e23077.
   Google Scholar
• Ott PA, HuX Z, Keskin DB, et al. An immunogenic personal neoantigen vaccine for patients with melanoma. Nature. 2017;547(7662):217.
   PubMed Web of Science ®Google Scholar
• Chee J, Robinson BWS, Holt RA, et al. Immunotherapy for lung malignancies: from gene sequencing to novel therapies. Chest. 2017 2017 Apr 01;151(4):891–897.
   PubMed Web of Science ®Google Scholar
• Snyder A, Makarov V, T M, et al. Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma [research-article]. 2014 2014 Dec 03 Available from http://dxdoiorg/101056/NEJMoa1406498.
   Google Scholar
• Brown SD, Warren RL, Gibb EA et al.Neo-antigens predicted by tumor genome meta-analysis correlate with increased patient survivalGenome Res20142014 May 01245743–750
   PubMed Web of Science ®Google Scholar
• Rajasagi M, Shukla SA, Fritsch EF, et al. Systematic identification of personal tumor-specific neoantigens in chronic lymphocytic leukemia. Blood. 2014;124(3):453–462.
   PubMed Web of Science ®Google Scholar
• Robbins PF, Lu Y-C, El-Gamil M, et al. Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells. Nat Med. 2013;19(6):747.
   PubMed Web of Science ®Google Scholar
• Champiat S, Dercle L, Ammari S, et al. Hyperprogressive disease is a new pattern of progression in cancer patients treated by anti-PD-1/PD-L1. Clin Cancer Res. 2017;23(8):1920–1928.
   PubMed Web of Science ®Google Scholar
• Sharon E. Can an immune checkpoint inhibitor (sometimes) make things worse? Clin Cancer Res. 2017;23(8):1879–1881.
   PubMed Web of Science ®Google Scholar
• Saâda-Bouzid E, Defaucheux C, Karabajakian A, et al. Hyperprogression during anti-PD-1/PD-L1 therapy in patients with recurrent and/or metastatic head and neck squamous cell carcinoma. Ann Oncol. 2017;28(7):1605–1611.
   PubMed Web of Science ®Google Scholar
• Kato S, Goodman A, Walavalkar V, et al. Hyperprogressors after Immunotherapy: analysis of genomic alterations associated with accelerated growth rate. Clin Cancer Res. 2017;23(15):4242–4250.
   PubMed Web of Science ®Google Scholar
• Hundal J, Carreno BM, Petti AA, et al. pVAC-Seq: A genome-guided in silico approach to identifying tumor neoantigens. Genome Med. 2016 2016 Jan 29;8. doi: 10.1186/s13073-016-0264-5.
   PubMed Web of Science ®Google Scholar
• Sahin U, Derhovanessian E, Miller M, et al. Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer. Nature. 2017;547(7662):222.
   PubMed Web of Science ®Google Scholar
• Bethune MT, Joglekar AV. Personalized T cell-mediated cancer immunotherapy: progress and challenges. Curr Opin Biotechnol. 2017;48(Supplement C):142–152.
   PubMedGoogle Scholar
• Subbiah V, Kurzrock R. Universal genomic testing needed to win the war against cancer: genomics is the diagnosis. JAMA Oncol. 2016 ;2(6):719.
   PubMed Web of Science ®Google Scholar